Amphotericin B
- Generic Name
- Amphotericin B
- Brand Names
- Abelcet, Ambisome, Amphotec, Fungizone
- Drug Type
- Small Molecule
- Chemical Formula
- C47H73NO17
- CAS Number
- 1397-89-3
- Unique Ingredient Identifier
- 7XU7A7DROE
- Background
Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
- Indication
Used to treat potentially life threatening fungal infections.
- Associated Conditions
- Coccidioidomycosis, Fungal Infections, Histoplasmosis, Invasive Aspergillosis, Invasive Fungal Infections, Leishmaniasis, Meningitis, Cryptococcal, Meningitis, Fungal, Mucocutaneous Leishmaniasis, Mycotic endophthalmitis, Penicillium marneffei infection, Visceral Leishmaniasis, Candidal cystitis, Disseminated Cryptococcosis, Fungal osteoarticular infections, Ocular aspergillosis, Refractory aspergillosis, Severe Coccidioidomycosis, Severe Cryptococcosis, Severe Fungal infection caused by Basidiobolus spp., Severe Fungal infection caused by Conidiobolus spp., Severe Fungal infection caused by sporotrichosis spp., Severe Histoplasmosis, Severe Mucocutaneous leishmaniasis, Severe North American blastomycosis, Severe Systemic candidiasis
Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients
- Conditions
- Lung Transplant Recipient
- Interventions
- Drug: Regular standard of care medication
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2011-10-19
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 4
- Registration Number
- NCT01254708
- Locations
- 🇨🇦
University Health Network/ Toronto General Hospital, Toronto, Ontario, Canada
Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh
- Conditions
- Visceral Leishmaniasis
- Interventions
- Drug: liposomal amphotericin B + paromomycinDrug: liposomal amphotericin B + miltefosine
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 602
- Registration Number
- NCT01122771
- Locations
- 🇧🇩
Bhaluka UZHC, Bhaluka, Mymensingh, Bangladesh
🇧🇩Gaffargaon, Gaffargaon, Mymensingh, Bangladesh
🇧🇩Community Based Medical College, Trishal, Mymensingh, Bangladesh
Liver Transplant European Study Into the Prevention of Fungal Infection
- Conditions
- Liver TransplantationMycoses
- Interventions
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 350
- Registration Number
- NCT01058174
Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation
- Conditions
- Invasive Pulmonary Aspergillosis
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2009-09-30
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 400
- Registration Number
- NCT00986713
- Locations
- 🇨🇳
Beijing Chaoyang Hospital,Affiliate of Capital Medical University, Beijing, Beijing, China
High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
- Conditions
- Cryptococcal MeningitisHIV Infections
- Interventions
- First Posted Date
- 2009-04-22
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 168
- Registration Number
- NCT00885703
- Locations
- 🇺🇬
Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site, Kampala, Uganda
🇿🇦Durban International Clinical Research Site CRS, Durban, KwaZulu-Natal, South Africa
🇺🇸University of Southern California CRS, Los Angeles, California, United States
To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar
- Conditions
- Leishmaniasis, Visceral
- Interventions
- Drug: Amphotericin B Lipid emulsion
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2011-06-02
- Lead Sponsor
- Bharat Serums and Vaccines Limited
- Target Recruit Count
- 500
- Registration Number
- NCT00876824
Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis
- Conditions
- Visceral Leishmaniasis
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2010-02-11
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 634
- Registration Number
- NCT00696969
- Locations
- 🇮🇳
Kala-azar medical centre, Muzaffarpur, Bihar, India
🇮🇳Rajendra Memorial research Institute, Patna, Bihar, India
CRITIC - Treatment of Candidemia and Invasive Candidiasis
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 39
- Registration Number
- NCT00670657
- Locations
- 🇮🇹
Gilead Sciences Srl, Milan, Italy
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis
- Conditions
- Visceral Leishmaniasis
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- Banaras Hindu University
- Target Recruit Count
- 400
- Registration Number
- NCT00628719
- Locations
- 🇮🇳
Kala-azar Medical Research Center, Rambag Road, Muzaffarpur, India
Antimicrobial PK in Infants With Suspected or Confirmed Infection
- Conditions
- Infection
- Interventions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2012-11-19
- Lead Sponsor
- Duke University
- Target Recruit Count
- 450
- Registration Number
- NCT00491426
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of California at San Diego, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.